

## LABORATORY REPORT

QC ACCOUNT (WARDE) 300 W. TEXTILE ANN ARBOR MI 48108

#### **EXAMPLE, REPORT**

WX0000003481 F 12/08/1988 34 Y

Referral Testing

Collected: 03/19/2021 16:48 Received: 03/19/2021 16:48

<u>Test Name</u> <u>Result</u> <u>Flag Ref-Ranges</u> <u>Units</u> <u>Site</u>

Rituxan Senitivity (CD20)

Specimen Source BLOOD QCRL
Appearance SEE NOTE QCRL

The sample consists of 41% granulocytic cells, 46% lymphocytoid cells,

and 8% monocytoid cells.

Viable cells/100 cells 64 % QCRL
Cells CD20/100 cells SEE NOTE QCRL

0% of the lymphocytes express the CD19+phenotype.

0% of selected lymphocytes are positive for CD20.

### Interpretive Guide:

Rituxan is a genetically engineered chimeric murine/human monoclonal antibody directed against CD20 antigen found on the surface of normal and malignant B lymphocytes (1). This antigen is expressed on the surface of >90% of B cell non-Hodgkin's lymphomas (NHL) and binding to it is a necessary prerequisite for Rituxan's antitumor effect (2). As subtypes of NHL may differ in their response to Rituxan (3,4), determination of drug sensitivity is important in choosing therapy.

#### References:

- 1. Reff et a. Depletion of B-cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435-445, 1994.
- 2. Anderson et al. Expression of human B cell associated antigens on leukemias and lymphomas: A model of human B cell differentiation. Blood 63:1424-1433, 1984.
- 3. Maloney et al. Results of phase 1 multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 14:3266-3274, 1997.
- 4. Maloney et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188-2195, 1997.

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute San Juan Capistrano. It has not been cleared or approved by FDA. This assay has

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL,  $\,$  . - NOT TESTED

C319000011 WX0000003481 Printed D&T: 12/01/23 10:22 Ordered By: CLIENT CLIENT WX0000000000000003

Kajal V. Sitwala, MD, PhD - Medical Director Form: MM RL1 PAGE 1 OF 2



# LABORATORY REPORT

QC ACCOUNT (WARDE) 300 W. TEXTILE ANN ARBOR MI 48108 **EXAMPLE, REPORT** 

WX0000003481 F 12/08/1988 34 Y

**Referral Testing** 

Collected: 03/19/2021 16:48 Received: 03/19/2021 16:48

Test Name Result Flag Ref-Ranges Units Site

been validated pursuant to the CLIA regulations and is used for

clinical purposes.

Test Performed at:

Quest Diagnostics Nichols Institute

33608 Ortega Highway

San Juan Capistrano, CA 92690-6130 I Maramica MD, PhD, MBA

**Reported Date:** 03/19/2021 16:49 RITFC

Performing Site:

QCRL: QUEST DIAGNOSTICS REFERENCE LAB CAPISTRANO 33608 Ortega Highway San Juan Capistrano CA 92675

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED

C319000011 WX0000003481 Printed D&T: 12/01/23 10:22 Ordered By: CLIENT CLIENT WX0000000000000003

Kajal V. Sitwala, MD, PhD - Medical Director Form: MM RL1 PAGE 2 OF 2